Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Amgen Inc. | Daxdilimab (HZN-7734) | Dermatomyositis | Phase 2 | Intravenous | Immunology | |
| Amgen Inc. | TEPEZZA (Teprotumumab) | Thyroid Eye Disease (TED) - chronic | Phase 3 | Intravenous | Opthalmic | |
| Amgen Inc. | Rocatinlimab (AMG 451/KHK4083) - (HORIZON) | Moderate to severe atopic dermatitis | Phase 3 | Ongoing | Subcutaneous | Immunology |
| Amgen Inc. | Tezepelumab - (NAVIGATOR) | Asthma and comorbid nasal polyps | Phase 3 | Data Released | Subcutaneous | Respiratory |
| Amgen Inc. | KHK4083/AMG 451 - (ROCKET) | Atopic dermatitis | Phase 3 | Intravenous | Immunology | |
| Amgen Inc. | TAVNEOS with Rituximab or a cyclophosphamide-containing regimen | Active ANCA-associated vasculitis | Phase 3 | Enrollment Initiation | Oral | Immunosuppressant |
| Amgen Inc. | AMG 104 (AZD8630) | healthy volunteers and patients with asthma | Phase 2 | Trial Planned | Intravenous | Respiratory |
| Amgen Inc. | Bemarituzumab (FPA144) + chemo - (FORTITUDE-101) | Gastric and gastro-esophageal junction cancer | Phase 3 | Data Released | Intravenous | Oncology |
